Malignes Melanom

Winkler, Julia; Buder‐Bakhaya, Kristina; Dimitrakopoulou-Strauß, Antonia; Enk, Alexander H.; Hassel, Jessica C.

doi:10.1007/s00117-017-0281-4

Cited by 5 publications

(3 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Melanoma is well known for its aggressive clinical behavior and therapeutic resistance. 1 , 2 Although early stages of melanoma can be removed by surgery, with high patient survival rates, metastatic melanoma has poor prognosis. Despite recent progress in the treatment of late-stage melanoma, and in particular, the advances in the development of novel targeted therapy and immunotherapy approaches, the overall outcome of patients with metastatic melanoma remains poor.…”

Section: Introductionmentioning

confidence: 99%

Sinomenine inhibits the growth of melanoma by enhancement of autophagy via PI3K/AKT/mTOR inhibition

Sun¹,

Zheng²,

Liu³

et al. 2018

DDDT

View full text Add to dashboard Cite

BackgroundMelanoma is a common skin tumor in adults with high metastasis and mortality rates. Thus, finding a better effective approach to treat melanoma has become very urgent. Sinomenine (SIN), the major active compound of Sinomenium acutum, has shown antitumorigenic activities in certain cancers. However, its role in melanoma remains unclear.PurposeThis study aimed to explore the effects of SIN on melanoma in vitro and in vivo, in addition to exploring the underlying mechanism.MethodsMouse melanoma cell B16-F10 treated by SIN was analyzed by CCK8 assay and flow cytometry. Melanoma xenograft model was then established by subcutaneously injection with B16-F10 cells. Tumor growth was measured by immunohistochemistry. To further investigate the relative mechanism, the autophagy and PI3K/Akt/mTOR pathway were examined by immunofluorescence and Western blot.ResultsOur results revealed that SIN dose dependently inhibited the proliferation of B16-F10 cells in vitro and attenuated melanoma growth in vivo. In addition, SIN treatment promoted the apoptosis of B16-F10 cells in a dose-dependent manner, as demonstrated by the increase in apoptotic cells, Bax/Bcl-2 ratio, and caspase-3 activity. Moreover, preconditioning with SIN dramatically enhanced autophagy activity by increasing Beclin-1 and LC3II/LC3I expression, in addition to decreasing p62 expression and augmenting the number of LC3 puncta, in B16-F10 cells. More importantly, autophagy inhibitor chloroquine partly abolished SIN’s effects on cell growth and apoptosis. Furthermore, our results showed that SIN-triggered activation of autophagy was mediated by PI3K/Akt/mTOR signaling pathway.ConclusionOur study has identified a novel function of SIN and provided a molecular basis for potential applications of SIN in the treatment of melanoma and other cancers.

show abstract

Section: Introductionmentioning

confidence: 99%

Sinomenine inhibits the growth of melanoma by enhancement of autophagy via PI3K/AKT/mTOR inhibition

Sun¹,

Zheng²,

Liu³

et al. 2018

DDDT

View full text Add to dashboard Cite

show abstract

“…MRI in metastatic melanoma (MM) is the most widely used for determining the presence of brain metastases because of superior sensitivity to CT/PET-CT for small lesions identification and their precise anatomical site evaluation. 15,17,18 Whole-Body MRI with diffusion-weighted imaging in bone metastases could play an important role in the diagnosis of bone solid tumor metastases. 19 PET has limitations that deserve consideration: among all it shows up areas of relevant uptake referred to inflammatory conditions that might be mistaken for cancers.…”

Section: Introductionmentioning

confidence: 99%

“…MRI in metastatic melanoma (MM) is the most widely used for determining the presence of brain metastases because of superior sensitivity to CT/PET‐CT for small lesions identification and their precise anatomical site evaluation . Whole‐Body MRI with diffusion‐weighted imaging in bone metastases could play an important role in the diagnosis of bone solid tumor metastases …”

Section: Introductionmentioning

confidence: 99%

Novel cancer therapies for advanced cutaneous melanoma: The added value of radiomics in the decision making process–A systematic review

et al. 2020

View full text Add to dashboard Cite

Advanced malignant melanoma represents a public health matter due to its rising incidence and aggressiveness. Novel therapies such as immunotherapy are showing promising results with improved progression free and overall survival in melanoma patients. However, novel targeted and immunotherapies could generate atypical patterns of response which are nowadays a big challenge since imaging criteria (ie Recist 1.1) have not been proven to be always reliable to assess response. Radiomics and in particular texture analysis (TA) represent new quantitative methodologies which could reduce the impact of these limitations providing most robust data in support of clinical decision process. The aim of this paper was to review the state of the art of radiomics/TA when it is applied to the imaging of metastatic melanoma patients.

show abstract

Neue Arzneimittel 2018

Fricke

Hein

Schwabe

2019

Arzneiverordnungs-Report 2019

View full text Add to dashboard Cite

Malignes Melanom

Abstract: An individual definition of the appropriate therapy for each patient is of particular importance. In the context of modern therapy regimens close patient monitoring is crucial.

Cited by 5 publications

References 43 publications

Sinomenine inhibits the growth of melanoma by enhancement of autophagy via PI3K/AKT/mTOR inhibition

Sinomenine inhibits the growth of melanoma by enhancement of autophagy via PI3K/AKT/mTOR inhibition

Novel cancer therapies for advanced cutaneous melanoma: The added value of radiomics in the decision making process–A systematic review

Neue Arzneimittel 2018

Contact Info

Product

Resources

About